Digital care platform : Log in to view your current dose, future shipment schedule, and lab review history (if applicable)
Repeat labs (A1c, lipids, kidney, liver) to track metabolic improvements, not just weight
Research shows that approximately two-thirds of patients regain weight when they stop GLP-1 receptor agonists, and even a 25 to 30 day gap can trigger some weight regain if dietary habits are not maintained
Common GLP-1 medications include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)
"With these exploratory findings of SURPASS-4, we are seeing the results of combined GIP/GLP-1 receptor agonists on the kidney function of patients with type 2 diabetes for the very first time," Heerspink said in a statement
Schedule 6: Poison [edit] Must use distinctive packaging and strong warnings to display the potential for: moderate to high toxicity